An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209)
Phase: Phase II clinical trials
Principal Investigator: Dott.ssa Giannatempo Patrizia
Main Facility: Oncologia Medica Genitourinaria
Drug: Enfortumab Vedotin, Pembrolizumab
Pathologies: Urological cancers (kidney, bladder, urinary tract, others)
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
Last update: 06/10/2026